Crossref
FDA approves drug to treat neurologic manifestations of Hunter syndrome
The Brown University Child & Adolescent Psychopharmacology Update · 2026-05 · 28 (5) · 8-8
DOI: 10.1002/cpu.31062 ↗At a glance
Journal article in The Brown University Child & Adolescent Psychopharmacology Update, published online on 2026-04-27.
Abstract (original language)
The U.S. Food and Drug Administration approved Avlayah to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).
Cite
APA
(2026). FDA approves drug to treat neurologic manifestations of Hunter syndrome. The Brown University Child & Adolescent Psychopharmacology Update, 28(5), 8-8. https://doi.org/10.1002/cpu.31062
Vancouver
FDA approves drug to treat neurologic manifestations of Hunter syndrome. The Brown University Child & Adolescent Psychopharmacology Update. 2026;28(5):8-8. doi:10.1002/cpu.31062
BibTeX
@article{euvimed2026,
title = {FDA approves drug to treat neurologic manifestations of Hunter syndrome},
journal = {The Brown University Child & Adolescent Psychopharmacology Update},
year = {2026},
volume = {28},
number = {5},
pages = {8--8},
doi = {10.1002/cpu.31062}
}
EUVIMED